Market Cap (In USD)
165.83 Million
Revenue (In USD)
30.05 Million
Net Income (In USD)
-39.7 Million
Avg. Volume
9123.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.76-8.962
- PE
- -
- EPS
- -
- Beta Value
- 1.403
- ISIN
- US63009J1079
- CUSIP
- 63009J107
- CIK
- 1760854
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Laurent Levy Ph.D.
- Employee Count
- -
- Website
- https://www.nanobiotix.com
- Ipo Date
- 2020-12-11
- Details
- Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
More Stocks
-
GABI
-
GANGESSECUGanges Securities Limited
GANGESSECU
-
KAEF
-
0288WH Group Limited
0288
-
ENGQFEngie SA
ENGQF
-
ASTRAMICROAstra Microwave Products Limited
ASTRAMICRO
-
MX
-
TBTCTable Trac, Inc.
TBTC